Sitte Thomas
PalliativNetz Osthessen, Fulda, Germany.
Wien Med Wochenschr. 2009 Dec;159(23-24):566-70. doi: 10.1007/s10354-009-0724-2.
Severe dyspnoea is the most threatening symptom of the dying and one of the main reasons for undesirable hospitalisation in end of life. Especially in home care there is a need for a noninvasive, safe and highly effective method for symptom control. Fentanyl is an appropriate drug because of its fast onset and short duration of action. Since 2003 medicated the Palliative Net Easthessia (PNO) more than 600 home care patients with nasal Fentanyl (naF). The method is simple and the user should bear in mind that the substance is highly effective. Both physician and pharmacist should inform themselves adequately before the first use about the basics of the manufacturing and use. Two typical case reports will be shown. Clinical experience let us assume that intranasal administration against dyspnoea is not inferior to the intravenous symptom control. In ambulant care caused by the use of the caring relatives or the patients themselves non-invasivity is a great advantage. Prospective studies are in need to prove the method.
严重呼吸困难是临终时最具威胁性的症状,也是临终时不必要住院的主要原因之一。特别是在家庭护理中,需要一种无创、安全且高效的症状控制方法。芬太尼因其起效快、作用时间短而成为一种合适的药物。自2003年以来,姑息性网络东施麻醉(PNO)已为600多名家庭护理患者使用鼻内芬太尼(naF)。该方法简单,使用者应牢记该药物效果显著。医生和药剂师在首次使用前都应充分了解其生产和使用的基本知识。将展示两个典型病例报告。临床经验使我们认为,鼻内给药治疗呼吸困难并不逊色于静脉内症状控制。在由护理亲属或患者自己进行的门诊护理中,无创性是一大优势。需要进行前瞻性研究来证实该方法。